Cascade-Responsive Zwitterionic Polyprodrugs Leverage Fast Transcytosis for Deep Tumor Penetration and Intracellular

Yufei Cao1, Moujiang Zheng1, Davron Turgunov2

  • 1School of Chemistry, State Key Laboratory of Fluorine & Nitrogen Chemicals, Institute of New Concept Sensors and Molecular Materials (INCSMM), Engineering Research Center of Energy Storage Materials and Devices, Ministry of Education, Xi'an Key Laboratory of Sustainable Polymer Materials, Xi'an Jiaotong University, Xi'an 710049, P.R. China.

Bioconjugate Chemistry
|April 21, 2026
PubMed

Insights

Intelligent nanomedicines overcome physiological barriers for enhanced cancer treatment. These zwitterionic polyprodrugs improve circulation, tumor penetration, and drug release, reducing systemic toxicity.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Drug Delivery

Background:

  • Clinical translation of nanomedicines is limited by physiological barriers (Circulation, Accumulation, Penetration, Internalization, Release).
  • Overcoming these barriers requires advanced nanocarrier designs for efficient drug delivery.

Purpose of the Study:

  • To develop intelligent zwitterionic polyprodrug micelles (P(OC7A-DOX)) that address the CAPIR barriers.
  • To engineer a nanoplatform with cascade tumor-specific responses for improved anticancer efficacy.

Main Methods:

  • Self-assembly of zwitterionic polyprodrugs into micelles with a hypoxia-responsive shell (POC7A) and a drug-loaded core (DOX).
  • Utilizing a glutathione (GSH)-cleavable disulfide bond for drug conjugation.
  • Evaluating the nanoplatform's performance in vitro and in vivo using 4T1 tumor-bearing mice.

Main Results:

  • The P(OC7A-DOX) micelles demonstrated prolonged circulation and enhanced tumor accumulation.
  • Charge reversal in the tumor microenvironment improved penetration and cellular internalization.
  • High intracellular GSH levels triggered efficient doxorubicin release, leading to significant tumor growth suppression.
  • Reduced systemic toxicity compared to free doxorubicin was observed.

Conclusions:

  • The developed nanoplatform successfully navigates physiological barriers, overcoming key challenges in nanomedicine translation.
  • This integrated approach offers a clinically promising strategy for effective and safer anticancer therapy.

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
148
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
160
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
127
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
288
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
167
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
168